Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.
about
Identification of a cell of origin for human prostate cancerFISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signalingProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cellsThe molecular basis for ethnic variation and histological subtype differences in prostate cancer.Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.Mouse models of prostate cancer: picking the best model for the question.Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cellsPTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancerPTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer.Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice.Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.PLZF mediates the PTEN/AKT/FOXO3a signaling in suppression of prostate tumorigenesis.Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancerPTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis.Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent.PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsA novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.Killin is a p53-regulated nuclear inhibitor of DNA synthesis.Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancerCytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer.Heterogeneity and clinical significance of ETV1 translocations in human prostate cancerNovel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.mTOR transcriptionally and post-transcriptionally regulates Npm1 gene expression to contribute to enhanced proliferation in cells with Pten inactivation.Does the microenvironment influence the cell types of origin for prostate cancer?ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy.
P2860
Q24594400-DF854AF2-A9A0-43E0-B979-53F3C4248CBCQ27851411-CA087E7D-7954-48AD-BCE3-38AC8E8162ADQ28586334-F3942042-009F-47B6-827D-D4E1FE98CD69Q30409623-D3F0EF79-F33C-4AF4-A5EC-5C4ADE820D66Q30654792-E67ECDB1-C330-4A83-BE92-86D0F865BFD8Q33835864-B6A9CEB6-D2C2-45F7-9E07-6A20600F1086Q33924077-BFD18012-2E50-4C73-8CFD-C2DE54AE6D71Q33940867-4C5A92FE-34B3-4EA3-BC3D-59CB5A6FA625Q34126555-65F96BDE-5B32-4C29-B6EE-3BAED8638332Q34484407-E083C29A-F876-4FE5-A1C6-6DCA4B17B4D6Q34602348-AB78E08D-3AF9-4568-B84C-8EFFB5FFCEAFQ34606601-61B4C12A-589B-4E67-899A-C218DEFCF84EQ34724225-137C34B0-CC4B-4822-AE87-D0377DFA7B9DQ34805348-50732643-045E-4877-A09C-0D4271F1D30BQ34951635-1A8714C2-C411-4A53-AB3D-73D201D07336Q35009891-2F3CFF27-4E2A-42DB-B64E-A133A7BED080Q35067277-70292C95-F00B-4B25-8569-17274B5F83C9Q35234584-638A19B3-F18C-4D56-85CA-393760E45707Q35540013-4A298B8C-4A59-405C-B328-74914068EAEDQ35586422-3A945D7A-D842-485C-91DB-741A2ADC1155Q35723957-71F2970B-AFE7-472C-ABF8-C1207B533BECQ35749654-27448738-EA77-4B11-AA4C-841E03B490B3Q35854235-D22C7E08-0624-45CF-9DB3-DDC3EAD343ADQ35903128-F1FA084E-DC85-46AD-A3D1-1006F9EE890BQ35962850-78846AE1-6D3D-42D6-9669-D0E3D31C8988Q36287422-292C719F-1EBB-4F16-9F48-5DAE9DA39800Q36437601-A22C4185-6587-41A1-88D7-B4530C9FCF0DQ36535351-C8D4D55A-DDE2-4A40-A293-2654D31F7A34Q36536821-7E434101-B154-44E9-A17E-B29DC8BBE4F5Q36610246-CD2B4BEF-7D93-4957-B677-1036276AEE5AQ36698824-3040BAE5-25C6-4E48-BF5E-20CEEC462746Q36724548-6158A4BA-1814-4696-B556-ED729DB01DFFQ36784882-16DD8798-E032-4AF6-B8A9-8E63C3DBDFDCQ36785930-99D04264-CC17-4845-BEFA-4882BA3A9C34Q36901964-904377BB-1914-4C93-B440-B39B94C7AB03Q36957063-BEFA27EE-3E79-4A6F-8036-55A039B24AF3Q37064582-B941648E-36F5-4B32-BDF6-71E658894717Q37257659-CBAA83E8-6080-4703-80FC-F1930B5A0453Q37383459-A034E5D1-51EF-4386-A95C-F7C0E3D21C93Q37536970-D1CEA75D-08B1-4B7B-9ADC-5E1BA1A2BF6B
P2860
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Interphase FISH analysis of PT ...... c intra-epithelial neoplasias.
@en
type
label
Interphase FISH analysis of PT ...... c intra-epithelial neoplasias.
@en
prefLabel
Interphase FISH analysis of PT ...... c intra-epithelial neoplasias.
@en
P2093
P1476
Interphase FISH analysis of PT ...... c intra-epithelial neoplasias.
@en
P2093
Andrew J Evans
Jane Bayani
Jean-Claude Cutz
Maisa Yoshimoto
Maria Zielenska
Paulo A S Nuin
P304
P356
10.1016/J.CANCERGENCYTO.2006.04.003
P577
2006-09-01T00:00:00Z